- Nuheara (NUH) completes clinical trial, conducted by the National Acoustics Laboratory (NAL), with all participants data being collected
- NAL is expected to publish the final clinical trial report by the end of this month
- The company says this is an important milestone for US FDA 510(K) submission and regulatory clearance
- Shares are trading flat today at 1.6 cents each
Hearing technology company, Nuheara (NUH) has completed its clinical trial, conducted by the National Acoustics Laboratory (NAL), with all participants data being collected.
NAL is expected to publish the final clinical trial report by the end of this month.
The company says this is an important milestone for US FDA 510(K) submission and regulatory clearance.
The company believes this step will move it closer to entering the US hearing aid market, in line with its expansion plans into global medical devices.
Managing Director and CEO Justin Miller is pleased with the company’s progress.
“This is another critical milestone completed in our journey to become recognised as a global medical device company,” he said.
“We appreciate the efforts of the team at NAL and those who have participated in this trial. We now look forward to the collation of the clinical trial data and the publication of the final report, which is due later this month.”
Shares are trading flat today at 1.6 cents each at 2:39 pm AEDT.